reviewsepsispathogenesishemostasisinflammationобзорсепсиспатогенезгемостазвоспаление1.Slutsky A., Whitehead Т., Zhang H. Clinical Trials Update: Future Direction for. In: Program and abstracts of the Fifth Toronto critical care medicine symposium. 2000. 34-38.2.Marshall J. С Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit. Care Med. 2001; 29 (7): 99-106.3.Bone R. С The pathogenesis of sepsis. Ann. Intern. Med. 1991; 115:457-469.4.Grinnell B. W., Joyce D. Recombinant human activated protein C: A system modulator of vascular function for treatment of severe sepsis. Crit. Care Med. 2001; 29 (7): 53-61.5.Sepsis: A significant Healthcare Challenge, www.sepsis.com <http://www.sepsis.com>.6.Малое В. А., Пак С. Г. Эволюция взгляда на роль бактериальных липополисахаридов в патологии человека. Вестн. РАМН 1997; 8: 33-38.7.Белобородое В. Б. Сепсис - современная проблема клинической медицины. Рус. мед. журн. 1997; 5 (24): 326-338.8.Coughlin S. R. Sol Sherry lecture in thrombosis: How thrombin "talks" to cells: Molecular mechanisms and roles in vivo. Arterioscler. Thromb. Vase. Biol. 1998; 18: 514-518.9.Gogos С A., Drosou E., Bassaris H. P. et al. Pro-versus antiinflammatory cytokine profile in patients with severe sepsis: A marker for prognosis and future therapeutic options. Infect. Dis. 2000; 181: 176-180.10.Volk D., Reinke P., Docke W. D. Immunostimulation with cytokines in patients with immunoparalysis. In: Marshall J. C,Cohen J. Immune response in the critically ill. Berlin: Spring r-Verlag; 1999. 393-404.11.Levi M., Van der Poll Т., ten Cate H. et al. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur. J. Clin. Invest. 1997; 27: 3-9.12.Esmon С. Т. Protein С anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit. Care Med. 2001; 29 (7): 48-52.13.Danner R. L., Elin R. J., Hosseini J. M. et al. Endotoxemia in human septic shock. Chest. 1991; 99: 169-175.14.Wheeler A. P., Bernard G. R. Treating patients with severe sepsis. N. Engl. J. Med. 1999; 340: 207-214.15.Carvalho A. C, Freeman N. J. How coagulation defects alter outcome in sepsis: Survival may depend on reversing procoag ulant conditions. J. Crit. Ulnes. 1994; 9: 51-75.16.Cohen J. Plenary session: sepsis in the critically ill: back to the future. In: Program and abstracts of the 30"' International educational and scientific symposium of the Society of critical care medicine. San Francisco, California; 2001. 44-48.17.Kidokoro A., Iba Т., Fukunaga M. et al. Alteration in coagulation and fibrinolysis during sepsis. Shock 1996; 5: 223-228.18.Martin G. S. Diagnosis and treatment of the critically ill sepsis patient. In: 30"' International educational and scientific symposium of the Society of critical care medicine. San Francisco, California; 2001. 122-126.19.Natanson C, Esposito С J., Banks S. M. The siren's songs of confirmatory sepsis trials: selection bias and sampling error. Crit. Care Med. 1998; 26: 1927-1931.20.Zeni F., Freeman В., Natanson S. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Ibid. 1997; 25: 1095-1100.21.Levi M., ten Gate H. Disseminated intravascular coagulation.N. Engl. J. Med. 1999; 34: 86-92.22.www.soros.karelia.ru <http://www.soros.karelia.ru>23.De Jonge E., Dekkers P. £., Creasey L. et al. Tissue factor pathway inhibitor (TFPI) dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-1129.24.Ten Gate J. W., Van der Poll Т., Levi M. et al. Cytokines: Triggers of clinical thrombotic disease. Thromb. and Haemost. 1997;78:415-419.25.Lorant D. E., Topham M. K., Whatley R. E. et al. Inflammato ry roles of P-selectin. J. Clin. Invest. 1993; 92: 559-570.26.Levi M., de Jonge E., van der Poll T. Rational for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit. Care Med. 2001; 29: 90-94.27.Levi M., de Jonge E., van der Poll T. Novel approaches to the management of disseminated intravascular coagulation. Crit. Care Med. 2000; 28: 20-24.28.Buller H. R., ten Gate J. W. Acquired antithrombin III deficiency: Laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate. Am. J. Med. 1989; 87: 44-48.29.Blauhut В., Kramar H., Vinazzer H. et al. Substitution of antithrombin III in shock and DIC: A randomized study. Thromb. Res. 1985; 39:81-89.30.Esmon C. T. The protein С Pathway. Crit. Care Med. 2000; 28: 44-48.31.Esmon С. Т. Inflammation and thrombosis: Mutual regulation by protein С Immunologist 1998; 6: 84-89.32.Grinnell B. W., Yan S. B. Novel antithrombotics based on modulation of the protein С pathway. Coron Artery Dis. 1998; 9: 89-97.33.Nawroth P. P., Stern D. M. Modulation of endothelial cell haemostatic properties by tumor necrosis factor. J. Exp. Med. 1986; 163: 740-745.34.Esmon С. Т. The endothelial cell protein С receptor. Thromb. and Haemost. 2000; 83: 639-643.35.Esmon C. T. Molecular events that control the protein С anticoagulant pathway. Ibid. 1993; 70: 29-35.36.Esmon С. Т., Fukudome K., Mather T. et al. Inflammation, sepsis, and coagulation. Haematologica 1999; 84: 254-259.37.Fisher С J., Yan S. B. Protein С levels as a prognostic indica- tor of outcome in sepsis and related diseases. Crit. Care Med. 2000; 28: 49-56.38.Garcia de Frutos P., Alim R. /., Hardig Y. et al. Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood 1994; 84: 815-822.39.Yan S. В., Grinnell B. W. Recombinant human protein C, protein S and thrombomodulin as antithrombotics. Perspect. Drug Discovery Design 1994; 1: 504-520.40.Yan S. В., Grinnell B. W. Anti-thrombotic and anti-inflammatory agents of the protein С anticoagulant pathway. Ann. Rep. Med. Chem. 1994; 11: 103-112.41.Mann K. G, van't Veer C, Cawthern K. et al. The role of tissue factor pathway in initiation of coagulation. Blood Coagul. Fibnnolys. 1998; 9 (suppl. 1): 3-7.42.Shimura M., Wada H., Wakita Y. et al. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am. J. Haematol. 1997; 45. 55: 169-174.43.Bakker H. M., Tans G, Janssen-Claessen T. et al. The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C.Eur. J. Biochem. 1992; 208: 171-178.44.Vervloet M., Thijs L., Hack C. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin. Thromb. Haemost. 1998; 24: 33-44.45.Bernard G. R., Hartman D. L., Helterbrand J. D. et a Recom-binant human activated protein С (rhAPC) produces a trend toward improvement in morbidity and 28 day survival in patients in severe sepsis. Crit. Care Med. 1999; 27: 4.46.Wesley E. F., Jr., Esmon С. Т., Fisher С. J. Jr. et al. New evolutions in understanding and managing patients with sepsis. Crit. Care Treatm. Updates 2000; 42-53.